# Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.

> **NCT07320963** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 52 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Chidamide
- **BIOLOGICAL:** Toripalimab
- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT07320963
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2027-03-28
- **Final completion:** 2028-03-28
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2026-03-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07320963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07320963, "Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07320963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*